The Haelo Phase 3 trial marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. ・Earlier mid-stage studies showed a 96% reduction in monthly attack rates, with 97% of patients ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

We'll know more about the company's medium-term prospects by the end of the year.

Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

Scientists have unveiled a CRISPR-based tool, ThermoCas9, capable of pinpointing and removing tumor DNA by detecting cancer-specific chemical markers, potentially sparing healthy cells. In parallel, ...

Scientists are laying the groundwork for treating one of the most common genetic conditions in humans. Research out today ...

A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a CRISPR genome editing technique that enables comparative analysis of the ...

Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable ...